Targeting interleukins for the treatment of inflammatory bowel disease - What lies beyond anti-TNF therapy?

Keyphrases

• Inflammatory Bowel Disease 100%
• Interleukin 100%
• Anti-TNF Therapy 100%
• Adverse Effects 33%
• Therapeutic Strategies 33%
• Therapeutic Target 33%
• Novel Therapeutics 33%
• Refractory Disease 33%
• Western World 33%
• Future Therapeutics 33%
• Relapsed Disease 33%
• Immunosuppressive Therapy 33%
• Interleukin-33 (IL-33) 33%
• Patient Morbidity 33%
• Interleukin-22 (IL-22) 33%
• Interleukin-27 (IL-27) 33%
• Interleukin-35 (IL-35) 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Inflammatory Bowel Disease 100%
• Interleukin Derivative 100%
• Cytokine 33%
• Recurrent Disease 33%
• Disease 33%
• Adverse Event 33%
• Immunosuppressive Agent 33%
• Interleukin 33 33%
• Interleukin 27 33%
• Interleukin 35 33%
• Interleukin 22 33%